AZN Astrazeneca plc
- Stocks
- Healthcare
- NASDAQ: AZN
Price (delayed)
$81.15
Market cap
$251.57B
P/E Ratio
30.28
Dividend/share
$1.57
EPS
$2.68
Enterprise value
$277.35B
Relative Growth:
Rel. Growth:
98
Relative Strength:
Rel. Strength:
67
Relative Valuation:
Rel. Valuation:
50
Relative Profitability:
Rel. Profitability:
95
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Highlights
AZN's price to earnings (P/E) is 76% lower than its 5-year quarterly average of 127.6
Astrazeneca's EPS has increased by 29% YoY and by 7% QoQ
AZN's debt is up by 3.8% since the previous quarter but it is down by 2.1% year-on-year
Key stats
What are the main financial stats of AZN
Market
Valuations
Earnings
Shares outstanding
3.1B
Market cap
$251.57B
Enterprise value
$277.35B
Price to earnings (P/E)
30.28
Price to book (P/B)
5.63
Price to sales (P/S)
4.45
PEG
1.05
EV/EBIT
23.73
EV/EBITDA
14.98
EV/Sales
4.91
Revenue
$56.5B
Gross profit
$45.98B
Operating income
$11.32B
Net income
$8.3B
EBIT
$11.69B
EBITDA
$18.51B
Free cash flow
$11.19B
Per share
Balance sheet
Liquidity
EPS
$2.68
EPS diluted
$2.65
Free cash flow per share
$3.61
Book value per share
$14.43
Revenue per share
$18.23
TBVPS
$17.15
Total assets
$112.42B
Total liabilities
$67.61B
Debt
$32.84B
Equity
$44.72B
Working capital
-$4.6B
Debt to equity
0.73
Current ratio
0.86
Quick ratio
0.67
Net debt/EBITDA
1.39
Margins
Efficiency
Dividend
EBITDA margin
32.8%
Gross margin
81.4%
Net margin
14.7%
Operating margin
20%
Return on assets
7.8%
Return on equity
19.8%
Return on invested capital
26.2%
Return on capital employed
14.8%
Return on sales
20.7%
Dividend yield
1.93%
DPS
$1.57
Payout ratio
58.4%
AZN stock price
How has the Astrazeneca stock price performed over time
Intraday
-1.07%
1 week
-1.31%
1 month
-4.88%
1 year
22.45%
YTD
23.86%
QTD
5.77%
Financial performance
How have Astrazeneca's revenue and profit performed over time
Revenue
$56.5B
Gross profit
$45.98B
Operating income
$11.32B
Net income
$8.3B
Gross margin
81.4%
Net margin
14.7%
AZN's net income is up by 29% year-on-year and by 7% since the previous quarter
AZN's operating income is up by 25% year-on-year and by 7% since the previous quarter
Astrazeneca's revenue has increased by 15% YoY and by 2.8% QoQ
The company's gross profit rose by 14% YoY and by 2.7% QoQ
Price vs fundamentals
How does AZN's price correlate with its fundamentals
Growth
What is Astrazeneca's growth rate over time
Valuation
What is Astrazeneca stock price valuation
P/E
30.28
P/B
5.63
P/S
4.45
EV/EBIT
23.73
EV/EBITDA
14.98
EV/Sales
4.91
AZN's price to earnings (P/E) is 76% lower than its 5-year quarterly average of 127.6
Astrazeneca's EPS has increased by 29% YoY and by 7% QoQ
AZN's equity is up by 13% year-on-year and by 9% since the previous quarter
The stock's price to book (P/B) is 6% more than its last 4 quarters average of 5.3 but 6% less than its 5-year quarterly average of 6.0
Astrazeneca's revenue has increased by 15% YoY and by 2.8% QoQ
The stock's price to sales (P/S) is 9% more than its last 4 quarters average of 4.1 but 3.3% less than its 5-year quarterly average of 4.6
Efficiency
How efficient is Astrazeneca business performance
The return on assets is up by 22% year-on-year and by 5% since the previous quarter
The company's return on equity rose by 18% YoY and by 3.1% QoQ
Astrazeneca's return on sales has increased by 8% YoY and by 4% QoQ
Astrazeneca's return on invested capital has increased by 6% YoY and by 4.4% QoQ
Dividends
What is AZN's dividend history
DPS
$1.57
Dividend yield
1.93%
Payout ratio
58.4%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Astrazeneca financials performed over time
The company's total assets is 66% higher than its total liabilities
The company's total assets rose by 8% YoY and by 6% QoQ
AZN's current ratio is down by 4.4% from the previous quarter and by 3.4% YoY
AZN's debt is 27% smaller than its equity
AZN's debt to equity is down by 14% year-on-year and by 5% since the previous quarter
AZN's equity is up by 13% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.